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have construct, face, and predictive validity, but current ani-
mal models do not always satisfy these validity criteria.
Additionally, animal models of depression rely mainly on
stress-induced behavioral changes. These stress-induced
models have limited validity, because stress is not a risk fac-
tor specific to depression, and the models do not recapitu-
late the recurrent and spontaneous nature of depressive
episodes. Although animal models exhibiting recurrent
depressive episodes or bipolar depression have not yet
been established, several researchers are trying to generate
such animals by modeling clinical risk factors as well as by
manipulating a specific neural circuit using emerging tech-
niques.
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INTRODUCTION
Depression imposes a large social burden due to
substantial impairment and disability in everyday
activities at work, school, and home; the limited eﬃcacy
of existing treatments; and a high rate of lifetime
prevalence. Depression is also a risk factor for somatic
diseases such as cardiovascular disease (Lin et al.,
2014), and maternal depression has been shown to aﬀect
child development (Ohoka et al., 2014).
Approximately 16% of patients seeking treatment for a
major depressive episode have bipolar disorder (Angst
et al., 2011). Bipolar disorder is characterized by recur-
rent depressive and (hypo)manic episodes. The course
of bipolar disorder is dominated by the depressive state
(Judd et al., 2002, 2003). Though bipolar depression is
associated with characteristic features such as early
onset, psychotic symptoms, hypersomnia, and hyperpha-
gia (Mitchell et al., 2008), there is no ‘‘point of rarity”
between depressive states of unipolar depression and
bipolar disorder.
All the currently available antidepressants share a
fundamental mechanism of action, i.e., the modulation
of monoaminergic neurotransmission (Berton and
Nestler, 2006). Studies concerned with the development
of new antidepressants with novel mechanisms of action
have had limited success. This may be partly due to the
lack of adequate animal models of depression and less
knowledge about the disease mechanism, which are
almost two sides of the same coin.
Although antidepressants were developed to
ameliorate the symptoms of acute depression and
approved based on this eﬃcacy (Inada and Inagaki,
2015), they are also prescribed to prevent relapses
(Piek et al., 2014). Almost half of the patients that recover
from major depressive episodes experience relapse
(Belsher and Costello, 1988).
Several drugs, such as lithium, lamotrigine,
olanzapine, quetiapine, and aripiprazole, are known to
have preventive eﬀects for bipolar disorder (Kanba
et al., 2013), some of which might also be eﬀective for
unipolar depression (Zhou et al., 2015). However, none
of these drugs were developed speciﬁcally for bipolarrg/licenses/by/4.0/).
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lepsy with their uses extended to the treatment of bipolar
disorder.
This lack of novel treatment speciﬁcally designed for
the prevention of mood episodes in recurrent depression
and bipolar disorder is due at least in part to the lack of
animal models exhibiting spontaneous episodes of
depression and/or mania. The development of new
animal models exhibiting recurrent spontaneous mood
episodes is therefore indispensable for the development
of new drugs that are eﬀective in the prevention of
mood episodes.
In this article, the issues surrounding animal models of
recurrent or bipolar depression are discussed.
CAN MOOD DISORDERS BE MODELED BY
ANIMALS?
An animal model of mental disorder should ideally satisfy
three validity criteria: construct, face, and predictive
validity (Kato et al., 2007; Nestler and Hyman, 2010). In
reality, most researchers utilize models that satisfy only
a subset of these three criteria.
Construct validity
Construct validity refers to how the mechanism of a
disease is shared between a disease and the model.
Recurrent depression and bipolar disorder are widely
thought to be caused by gene-environment interactions.
One ideal animal model would be genetically modiﬁed
animals carrying a genetic mutation that confers a
strong risk of a disease with high penetrance. However,
research has yet to identify the genes that exert a
strong eﬀect on recurrent depression and bipolar
disorder (Kato, 2015), and many patients do not have
such mutations with strong eﬀects. Thus, the other ideal
model would be an animal model that is created by
gene-environment interaction, in which a genetic model
of a common polymorphism is exposed to an environmen-
tal risk factor interacting with the polymorphism.
Among environmental factors, perinatal infection
(Parboosing et al., 2013), maternal smoking during preg-
nancy (Talati et al., 2013), and perinatal complications are
established risk factors for bipolar disorder, but also apply
to schizophrenia (Schmitt et al., 2014). Childhood mal-
treatment also is a common risk factor for depression
and bipolar disorder (Daruy-Filho et al., 2011) as well as
other mental disorders, such as personality and anxiety
disorders.
Psychosocial stress is a risk factor for depressive
episodes, and is frequently used in animal models,
despite the fact that it is common to both mental
disorders and general medical illnesses. For example,
social defeat stress, which is currently widely used as
an animal model for depression in neuroscience
research (Tsankova et al., 2006), was initially developed
for the study of hypertension (Henry et al., 1967).
Additionally, the learned helplessness model, which is fre-
quently used in the study of depression, is also used for
the study of gastric ulcers (Pare and Redei, 1993).
When stress-induced animal models are used fordepression research, the confounding eﬀects of somatic
factors should also be considered.
Thus, as discussed above, many of the current animal
models rely on limited construct validity.
Face validity
Face validity refers to how the signs and symptoms in
animal models are similar to the disease. In clinical
settings, recurrent depression and bipolar disorder are
deﬁned by the DSM-5 (Diagnostic and Statistical
Manual of Mental Disorders, ﬁfth edition) criteria
(American Psychiatric Association, 2013). The DSM-5 cri-
teria for depressive and manic episodes contain several
items that rely solely on subjective experience. These
include ‘‘depressed mood,” ‘‘feelings of worthlessness,”
and ‘‘thoughts of death” for major depressive episodes,
and ‘‘elevated mood,” ‘‘increased self-esteem,” and ‘‘ﬂight
of ideas” for manic episodes. Therefore, face validity is
perhaps more diﬃcult to attain in animal models than
the other mentioned criteria. Nonetheless, it should be
noted that certain symptoms of depressive and manic epi-
sodes, such as sleep disturbances, appetite changes, and
agitation/retardation can be reasonably deﬁned, even in
animals, by means of behavioral or physiological mea-
surements. For example, sleep disturbances have been
detected by electroencephalography (Moreau et al.,
1995), and increases in food cravings have been detected
by the progressive ratio operant procedure (Willner et al.,
1998) in the chronic mild stress model. We used a behav-
ioral test battery to assess the behavioral phenotype of
Wfs1 knockout mice, a possible animal model of depres-
sion, and found that the mice showed an increased
latency to movement in the passive avoidance test and
a longer escape latency in the Morris water maze task
in spite that there was no diﬀerence of the distance trav-
eled. We interpreted these ﬁndings as reﬂective of psy-
chomotor retardation, that is, slow voluntary movement
(Kato et al., 2008). Therefore, we should examine
whether an animal model meets the clinical criteria for
depression or mania as far as possible. Needless to
say, there are fundamental diﬀerences in behavioral char-
acteristics between humans and other animals. For
example, humans are diurnal whereas many animals
used as animal models are nocturnal. These behavioral
diﬀerences between species should be taken into
consideration.
In addition to modeling the symptoms of depression
and mania, it is important to model the clinical course of
these diseases. In the DSM-5 criteria, major depressive
disorder, recurrent, and bipolar I (or II) disorder are
deﬁned by characteristic clinical courses that consist of
combinations of major depressive and/or (hypo)manic
episodes.
DSM-5 is deﬁned by signs and symptoms that either a
physician can observe or a patient experiences. Recently,
the National Institute of Mental Health of the United States
has started to use Research Domain Criteria (RDoC)
instead of DSM-5 criteria for research purposes (Casey
et al., 2013). RDoC deﬁnes mental disorder by behavioral
and neurobiological measures on ﬁve domains: Negative
Valence Systems, Positive Valence Systems, Cognitive
Table 1. Representative animal models of depression
Name Reference Citations
Forced swimming test Porsolt et al. (1977) 2,129
Tail suspension test Steru et al. (1985) 1,153
Learned helplessness Maier and Seligman
(1976)
1,001
Maternal separation Plotsky and
Meaney (1993)
984
Chronic unpredictable mild
stress
Willner et al. (1987) 828
Immune activation Yirmiya (1996) 316
Prenatal stress Mueller and Bale
(2008)
288
Social defeat stress Henry et al. (1967) 213
Dorsal raphe-speciﬁc HTT
knockout mice
Lira et al. (2003) 196
Flinders sensitive line rats Overstreet (1986) 102
Olfactory bulbectomized rats Cairncross et al. 71
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Regulatory Systems. Some measures in these domains
might reﬂect endophenotypes (Insel and Cuthbert,
2009). Though the RDoC is not intended for use to diag-
nose patients, if this approach is successful, RDoC might
facilitate the translation of research ﬁndings from animals
to humans and vice versa, because these behavioral and
neurobiological measures could be assessed equally in
animals and humans.
It is also important to note that behavioral changes
characteristic to depression also can be caused by
general disease. As is the case for the learned
helplessness test noted above, stress exposure can
aﬀect not only brain function but also gastrointestinal,
cardiac, and other organ functions. It is therefore
important to rule out the direct eﬀects of impairment of
other organs on model behavior.(1977)
Neonatal clomipramine
administration
Mirmiran et al.
(1980)
15
Citation numbers were obtained from the Web of Science, and are current as of
March 31, 2015. The original articles describing each animal model were used
whenever possible.Predictive validity
Predictive validity refers to the commonality of the eﬀect
of medications on a disease and behaviors of an animal
model of the disease. Some past depression models,
such as the olfactory bulbectomized (OB) rat, have
relied solely on predictive validity. Olfactory
bulbectomies have been shown to cause hyperactivity
and aggression symptoms in rats, which are improved
by the administration of antidepressants (Kelly et al.,
1997). In the case of the OB rat as a model of depression,
predictive validity was emphasized, and face and con-
struct validities were ignored. Another problem encoun-
tered in animal models of depression is the duration of
action of the antidepressants. In clinical settings, antide-
pressants exert their eﬀect after a week of treatment.
However, in the case of the widely cited forced swimming
test, antidepressants were administered just before the
animals were made to swim (Porsolt et al., 1977). In this
case, we should be prudent about claiming that the eﬃ-
cacy of this test accurately reﬂects the clinical action of
the drugs being tested. On the other hand, chronic antide-
pressant treatment is required for the eﬃcacy observed
on the novelty-suppressed feeding test (Bodnoﬀ et al.,
1988). However, this test is for anxiety rather than depres-
sion. Notably, the requirement of neurogenesis is diﬀerent
between the forced swimming and novelty-suppressed
feeding tests such that neurogenesis is not necessary in
the former test (Holick et al., 2008) but is necessary in
the latter test (Santarelli et al., 2003). Therefore, one
should consider which behavioral test is the best suited
to test the predictive validity of an animal model.
It should be noted that predictive validity is not always
necessary, because many patients are resistant to
currently available drugs, and drugs for such refractory
patients should be developed using new animal models.DEPRESSION MODELS
The representative animal models of depression are
summarized in Table 1.
The forced swimming test is the most popular
paradigm among the listed models, as is indicated by
the extremely high number of citations of the originalreport. The forced swimming and tail suspension tests
share the common feature of apparent ‘‘behavioral
despair.” However, it has been noted that immobility in
these tests does not always indicate behavioral despair,
but rather reﬂects a successful energy-saving coping
strategy (West, 1990). These models should therefore
not be considered genuine ‘‘depression models,” but
rather may be tests for antidepressant drugs acting on
monoaminergic systems (Reneric and Lucki, 1998).
Whereas the learned helplessness (Maier and
Seligman, 1976), chronic unpredictable stress (Willner
et al., 1987), and social defeat models (Henry et al.,
1967) are used to investigate behavioral changes after
acute or chronic stress, the maternal separation (Plotsky
and Meaney, 1993), prenatal stress (Mueller and Bale,
2008), and neonatal clomipramine administration
(Mirmiran et al., 1980) models are used to investigate
perinatal or early environmental risk factors.
Other models include the immune activation model
(Yirmiya, 1996), which is used to evaluate sickness
behavior associated with infection, and the dorsal raphe-
speciﬁc serotonin transporter (HTT) knockout mice (Lira
et al., 2003) and Flinders Sensitive Line (FSL) rats
(Overstreet, 1986), both of which are used to model
genetic factors. In addition, as noted above, the OB rat
model (Cairncross et al., 1977) is not based on construct
validity.
The neurobiological basis of depression has been
extensively studied through stress-related models
(Krishnan and Nestler, 2008). For example, the neuro-
plastic theory of depression was established based on
the restraint stress model (Pittenger and Duman, 2008).
Additionally, each model exhibits a diﬀerent response
to antidepressants. For example, antidepressant
response is dependent on the behavioral paradigm in
the maternal separation model (Harrison and Baune,
2014), whereas the chronic unpredictable stress model
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and Nestler, 2006).
Though many of the current animal models of
depression utilize stress exposure as noted above, the
eﬀect of stress decreases with the progression of the
illness, and repeated exposure to stress can lead to
depressive episodes occurring spontaneously and
independently from stressful life events (Post, 1992).NEURAL CIRCUIT MODELS OF DEPRESSION
The above noted approaches have tried to model clinical
risk factors of depression such as psychosocial stress,
somatic factors, early adversity, perinatal environmental
factors, and genetic vulnerability. Meanwhile, the
development of optogenetics, a new technology to
manipulate speciﬁc neural circuits in living organisms
using opsins expressed by transgenes and light
illumination to speciﬁc brain regions, has enabled the
analysis of the role of speciﬁc neural circuits in speciﬁc
behaviors in living animals (Boyden et al., 2005). In partic-
ular, the role of neural circuits involving the amygdala in
anxiety-related behaviors has been extensively studied
using this technology (Deisseroth, 2014). This emerging
technology enables a new type of animal model, i.e.,
‘‘neural circuit models” of depression.
In this model, instead of satisfying the construct
validity by imposing risk factors for depression,
neurophysiological phenomena that are proposed to
occur in the brains of patients with depression are
directly simulated. Whereas electric stimulation or lesion
studies are able to examine the net eﬀect of excitatory
and inhibitory neurons on a particular brain area,
optogenetics can examine the role of a speciﬁc group of
neurons projecting from one brain region to the other;
for example, from the medial prefrontal cortex (mPFC)
to the dorsal raphe nucleus (DRN) (Warden et al.,
2012). Furthermore, the high temporal resolution of opto-
genetics enables the analysis of the relationship between
the stimulation of a group of neurons with diﬀerent ﬁring
patterns and the behavioral consequence (Chaudhury
et al., 2013).
Because the neural circuit mechanism of depression
has not yet been fully elucidated, the manipulation of a
candidate neural circuit is employed for this type of study.Role of dorsal raphe serotonergic neurons
Antidepressants are thought to exert their eﬀect by
enhancing serotonergic neurotransmission, but
corresponding neural circuit abnormalities in depression
are not yet well understood.
The stimulation of the axons of the mPFC neurons in
the DRN increased swimming behavior during forced
swimming (Warden et al., 2012), but did not increase loco-
motor activity in an open-ﬁeld test, which implicates a
speciﬁc role of the mPFC-DRN neural projection in the
immobility behavior observed during the forced swimming
test.
The optogenetic inhibition of GABAergic neurons in
the DRN prevented the acquisition of social avoidance
after social defeat (Challis et al., 2013), suggesting a roleof DRN inhibitory neurons in the susceptibility phenotype.
DRN GABAergic neurons receive inputs from the ventro-
medial prefrontal cortex (vmPFC) (Challis et al., 2014),
and optogenetic stimulation of these inputs enhanced
avoidance that resembled the resilient phenotype induced
by social defeat stress, whereas optogenetic inhibition
diminished the avoidance behavior.
In human experiments, serotonin deﬁciency in the
brain via tryptophan depletion increased delayed reward
discounting, and it was speculated that this might play a
role in depression (Schweighofer et al., 2008). The selec-
tive activation of DRN serotonergic neurons during a
delayed reward task decreased the premature cessation
of waiting. The eﬀect of increased waiting time was not
due to motor inhibition, and was not mediated by the
rewarding eﬀect of serotonergic neuron stimulation
(Miyazaki et al., 2014). This ﬁnding has been replicated
by other investigators (Fonseca et al., 2015).
Therefore, ﬁndings from the optogenetic manipulation
of serotonergic neurons might shed light on the role of
serotonin in depression.Role of ventral tegmental area dopaminergic neurons
The role of dopamine in depression is suggested by
decreased homovanillic acid, a metabolite of dopamine,
in the cerebrospinal ﬂuid of depressed patients, and the
eﬀects of some antidepressants on dopaminergic
systems (Kunugi et al., 2015).
The inhibition of ventral tegmental area (VTA)
dopaminergic neurons in mice results in ‘‘depression-
like” behaviors such as increased immobility time in the
tail suspension test and decreased sucrose preference
(Tye et al., 2013). The stimulation of VTA dopaminergic
neurons counteracted the increase in immobility time
and the decrease in sucrose preference due to chronic
mild stress (Tye et al., 2013).
However, the phasic stimulation of VTA dopaminergic
neurons in mice that experienced subthreshold social
defeat stress induced a susceptible phenotype, whereas
tonic stimulation did not (Chaudhury et al., 2013).
Therefore, this experiment directly proves the role of
VTA dopaminergic neurons in the susceptible phenotype
after social defeat stress, which was suggested by previ-
ous studies (Cao et al., 2010).
Although these two studies show apparently opposite
eﬀects of dopaminergic neurotransmission on
depression, depression should not be considered a
single homogeneous disease but rather a syndrome
comprised of a variety of diseases with diﬀerent
neurobiological mechanisms.Future directions
As discussed above, past optogenetic studies have
demonstrated the signiﬁcance of candidate neural
circuits in ‘‘depression-like” behaviors, such as
immobility in forced swimming and susceptibility to
social defeat stress (Warden et al., 2012; Chaudhury
et al., 2013; Tye et al., 2013). The manipulated neural cir-
cuits are candidate neural circuits implicated from the
T. Kato et al. / Neuroscience 321 (2016) 189–196 193action mechanism of antidepressants on the serotonergic
and dopaminergic systems.
Most importantly, none of the neural circuit models
has tested recurrent depressive episodes. To examine
the long-term consequence of neural circuit
manipulation, other techniques such as DREADD
(designer receptors exclusively activated by designer
drugs) (Urban and Roth, 2015) or DICE-K (doxycycline-
inhibited circuit-exocytosis knockdown) (Nakashiba
et al., 2008) would also be suitable. In DREADD, recep-
tors that are designed to be activated or inactivated by a
designer drug are expressed in a speciﬁc neural circuit,
and a designer drug CNO (clozapine N-oxide) is adminis-
tered to stimulate or inhibit this neural circuit. In DICE-K,
tetanus toxin, which inhibits exocytosis, is expressed in
a speciﬁc neural circuit to inhibit neural transmission
depending on doxycycline.
If future studies of genetic animal models identify
novel causative neural circuits, neural circuit
manipulation by emerging techniques such as
optogenetics will be useful to test whether the given
neural circuit is responsible for depression (Tye et al.,
2013). Though these new technologies are promising, dif-
ﬁculties in assessing face validity remain major problems
in the study of neural circuit models.Table 2. Putative animal models of recurrent mood episodes
Name Reference Citations
Clock mutant mice Roybal et al.
(2007)
307
a calcium/calmodulin-dependent
protein kinase II mutant mice
Yamasaki
et al. (2008)
102
Forebrain-speciﬁc mutant Polg
transgenic mice
Kasahara
et al. (2006)
71
Chronic amphetamine treatment Honma et al.
(1986)
58
Prokineticin receptor 2 mutant mice Jethwa et al.
(2008)
11
Repeated chronic mild stress Remus et al.
(2013)
-
Citation numbers were obtained from the Web of Science, and are current as of
March 31, 2015. The original articles describing each animal model were used
whenever possible.CURRENT STATUS OF ANIMAL MODELS OF
BIPOLAR DISORDER
There have been no established animal models of bipolar
disorder that exhibit both manic and depressive episodes.
Typical current animal models of mania involve drug-
induced hyperactivity or genetically modiﬁed animals
that exhibit continuous hyperactivity.
The most popular animal model of mania is the
amphetamine-induced hyperactivity model (Kara and
Einat, 2013). Hyperactivity caused by intracerebroventric-
ular injection of ouabain also has been used in animal
models of mania (el-Mallakh et al., 1995), based on the
hypothesis that Na+/K+-ATPase dysfunction is a feature
of bipolar disorder. Although genetically modiﬁed mice
exhibiting hyperactivity might also be considered animal
models of mania (Kara and Einat, 2013), these mice are
sometimes considered to be animal models of attention
deﬁcit/hyperactivity disorder (ADHD) as well (Russell,
2007). Furthermore, hyperactive mice also are consid-
ered to be animal models of schizophrenia (Gainetdinov
et al., 2001). Therefore, persistent hyperactivity observed
in mutant mice is not necessarily indicative of an accurate
animal model of mania, and construct and predictive
validity should be emphasized in these cases.
In this regard, the Shank3 overexpression model is of
exceptional interest. Han and colleagues generated
Shank3 transgenic mice based on the fact that the
duplication of chromosomal region 22q13, including the
SHANK3 gene, is associated with neurodevelopmental
disorders such as autism spectrum disorders, ADHD,
and schizophrenia. In addition, Shank3 has been
identiﬁed as a plausible candidate gene for these
phenotypes (Han et al., 2013). Because mice overex-
pressing Shank3 exhibit hyperactivity, the authorsinterpreted this ﬁnding as reﬂective of an ADHD symptom.
However, this condition was worsened by amphetamine
treatment, which runs contrary to the initial expectation
that amphetamine treatment would improve the hyperac-
tivity as is the case in patients with ADHD. To determine
the reason for this unexpected experimental result, the
authors closely examined the clinical records of two
patients carrying a duplication of SHANK3. They found
that one patient had epilepsy and ADHD that was non-
responsive to psychostimulants, and the other patient
had epilepsy and bipolar disorder. This clinical observa-
tion was consistent with the lack of eﬃcacy of ampheta-
mine in their model mice. Instead, they speculated that
valproate, an antiepileptic drug that is also eﬀective for
mania, might be eﬀective for their model mice. Indeed,
valproate was eﬀective in treating the hyperactivity of
the mice. These ﬁndings suggest that mice with Shank3
overexpression could serve as a model of valproate-
responsive mania.ANIMAL MODELS OF RECURRENT MOOD
EPISODES
None of the animal models described above exhibit
spontaneous recurrent mood episodes. A literature
search using the keywords ‘‘recurrent depression” and
‘‘animal model” yielded no relevant papers. However, to
the best of our knowledge, some studies do convey the
possibility of creating animal models that can be used to
investigate spontaneous mood episodes (Table 2).
Model mice carrying a dominant negative mutation of
the Clock gene have been utilized as animal models of
mania (Roybal et al., 2007). These mice exhibit persistent
hyperactivity, reduced behavioral despair, reduced anxi-
ety, sleep disturbances, and an increase in the reward
values of cocaine, sucrose, and intracranial self-
stimulation of the medial forebrain bundle. These pheno-
types were persistent rather than episodic, and some of
these behavioral features were normalized by lithium
treatment. However, since the manic-like phenotype
observed during the day disappeared at night, the
researchers speculated that the phenotype of the mice
is reﬂective of rapid mood cycling (Sidor et al., 2015).
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experience of a prior depressive episode would increase
susceptibility to future depressive episodes. To test this
hypothesis, they applied chronic mild stress to rats for
35 days, while controls were kept in their home cage.
After a 20-day recovery period, both groups of rats were
exposed to a second session of chronic mild stress for
15 days. The rats that had experienced the ﬁrst stress
session exhibited a more rapid decline in sucrose
consumption when compared with controls (Remus
et al., 2013). The researchers discussed this phe-
nomenon as a model of recurrent depression.
Honma and colleagues chronically treated rats with
methamphetamine by adding it to their drinking water.
Some of the rats failed to entrain to the light/dark cycle,
and exhibited a free-running period longer than 24 h
(Honma et al., 1986). Rats with suprachiasmatic nucleus
lesions treated with chronic methamphetamine occasion-
ally exhibited a circabidian, i.e., an approximately 48-h,
activity rhythm (Honma et al., 1992). These researchers
are currently studying the neurobiological basis of bipolar
disorder using this model (Honma et al., 2014).
Yamasaki et al. analyzed a mouse model
characterized by a heterozygous mutation of alpha
calcium/calmodulin-dependent protein kinase II. These
mice exhibited hyperactivity periods over an
approximately 1–2-week cycle (Yamasaki et al., 2008).
The researchers posited that this activity pattern resem-
bled periodic mood changes, which may be similar to
bipolar disorder.
The similarity between seasonal aﬀective disorder and
hibernation has been discussed in the literature
(Mrosovsky, 1988). Hibernation has not been observed
in mutant mice, but a related phenomenon known as daily
torpor has been reported in a mutant mouse line. Mice
carrying mutant prokineticin receptor 2 (Prokr2) exhibited
spontaneous and recurrent bouts of decreased locomotor
activity with a hypometabolic state lasting approximately
8 h at room temperature (Jethwa et al., 2008).
Kasahara and colleagues generated transgenic mice
with mutant mitochondrial DNA polymerase (Polg) to
model psychiatric symptoms observed in patients with a
mitochondrial disease, chronic progressive external
ophthalmoplegia. The mice exhibited an altered day/
night activity rhythm and periodic changes in wheel
running activity associated with the estrous cycle. These
phenotypes were normalized by lithium treatment.
Treatment with tricyclic antidepressants increased
activity levels. These ﬁndings suggest that mice are
able to exhibit mood disorder-like phenotypes (Kasahara
et al., 2006).CONCLUSION
Past animal models of depression have relied primarily on
stress-induced behavioral changes. No current animal
models have been established as accurate models of
recurrent or bipolar depression. This is partly due to the
lack of established causative genetic mutations of
recurrent depression or bipolar disorder. In order to
model recurrent depression or bipolar disorder inanimals, we must ﬁrst identify the genetic mutations that
strongly confer a risk for these disorders. Recent
ﬁndings have shown that de novo mutations play a role
in schizophrenia (Fromer et al., 2014; Takata et al.,
2014), and identiﬁcation of the de novo mutations that
cause recurrent depression and bipolar disorder would
enable further genetic modeling in animals.
Furthermore, behavioral characterizations should refer
to the clinical deﬁnitions of recurrent depression and bipo-
lar disorder in humans as the ‘‘gold standard” to deﬁne
mental disorders. To date, none of the animal models of
recurrent depression or bipolar disorder has been
assessed using DSM-5 or other clinical criteria. Further
consideration should be given as to how clinical diag-
noses in humans can be introduced into animal model
studies, while taking into account the diﬀerences in
behavioral characteristics among species.Acknowledgments—This work was supported by JSPS
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